DK2337849T3 - Faktor ix-polypeptidmutant, anvendelser deraf og fremgangsmåde til fremstiling deraf - Google Patents

Faktor ix-polypeptidmutant, anvendelser deraf og fremgangsmåde til fremstiling deraf Download PDF

Info

Publication number
DK2337849T3
DK2337849T3 DK09748260.8T DK09748260T DK2337849T3 DK 2337849 T3 DK2337849 T3 DK 2337849T3 DK 09748260 T DK09748260 T DK 09748260T DK 2337849 T3 DK2337849 T3 DK 2337849T3
Authority
DK
Denmark
Prior art keywords
fix
polypeptide
glu
seq
val
Prior art date
Application number
DK09748260.8T
Other languages
English (en)
Inventor
Paolo Simioni
Original Assignee
Uniqure Biopharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2337849(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B V filed Critical Uniqure Biopharma B V
Application granted granted Critical
Publication of DK2337849T3 publication Critical patent/DK2337849T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (9)

1. Modificeret FIX- (faktor IX) polypeptid til anvendelse i en medicinsk behandling i en daglig dosering på mellem 0,1 pg/kg og 400 pg/kg kropsvægt, hvilket modificeret FIX-polypeptid har mindst 70 % identitet med en SEQ ID NO: 1 eller SEQ ID NO: 2; hvor leucin er til stede ved en position svarende til position 338 af et umodificeret maturt FIX-polypeptid som identificeret ved SEQ ID NO: 2.
2. Polypeptid til anvendelse ifølge krav 1, hvor polypeptidet har mindst 90 % identitet med SEQ ID NO: 1 eller SEQ ID NO: 2.
3. Polypeptid til anvendelse ifølge et hvilket som helst af kravene 1-2, hvor behandling er ved oral, parenteral, rektal, inhalations- eller insufflationsadministration.
4. Polypeptid til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor polypeptidet er beregnet til anvendelse i behandlingen af en medfødt eller erhvervet koagulopati, en medfødt eller erhvervet hæmatologisk sygdom, en hæmoragisk forstyrrelse eller en anden kardiovaskulær sygdom.
5. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav ved behandling af hæmoragisk gastritis, uterusblødning eller hæmofili.
6. Polypeptid som defineret i et af kravene 1-3 til anvendelse i behandlingen af mindst én koagulopati.
7. Polypeptid til anvendelse ifølge et hvilket som helst af de foregående krav i behandling af hæmofili A eller hæmofili B.
8. Polypeptid til anvendelse ifølge et hvilket som helst af kravene 4 til 7, hvor polypeptidet er tilvejebragt i en farmaceutisk sammensætning, der omfatter polypeptidet og mindst én farmaceutisk acceptabel excipiens; hvilket modificeret FIX-polypeptid er til stede i den farmaceutiske sammensætning i en mængde, der er egnet til administration i en daglig dosering på mellem 0,1 pg/kg og 400 pg/kg kropsvægt.
9. Polypeptid til anvendelse ifølge krav 8, hvor den farmaceutiske sammensætning er formuleret til oral, parenteral, rektal, inhalations- eller insufflationsadministration.
DK09748260.8T 2008-09-15 2009-09-15 Faktor ix-polypeptidmutant, anvendelser deraf og fremgangsmåde til fremstiling deraf DK2337849T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
PCT/EP2009/061935 WO2010029178A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production

Publications (1)

Publication Number Publication Date
DK2337849T3 true DK2337849T3 (da) 2018-10-01

Family

ID=41397565

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19174517.3T DK3581650T3 (da) 2008-09-15 2009-09-15 Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf
DK09748260.8T DK2337849T3 (da) 2008-09-15 2009-09-15 Faktor ix-polypeptidmutant, anvendelser deraf og fremgangsmåde til fremstiling deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19174517.3T DK3581650T3 (da) 2008-09-15 2009-09-15 Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf

Country Status (17)

Country Link
US (11) US9249405B2 (da)
EP (5) EP2337849B1 (da)
CA (1) CA2737094C (da)
CY (2) CY1125885T1 (da)
DK (2) DK3581650T3 (da)
ES (2) ES2940323T3 (da)
FI (2) FI3581650T3 (da)
FR (1) FR23C1028I1 (da)
HK (1) HK1244507A1 (da)
HR (2) HRP20230259T1 (da)
HU (2) HUE061345T2 (da)
LT (2) LT3581650T (da)
PL (2) PL3581650T3 (da)
PT (1) PT3581650T (da)
SI (1) SI3581650T1 (da)
TR (1) TR201813067T4 (da)
WO (1) WO2010029178A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3581650T3 (fi) * 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
IN2015DN01404A (da) 2012-07-25 2015-07-03 Catalyst Biosciences Inc
FI2956477T4 (fi) 2013-02-15 2024-04-24 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3313991B1 (en) * 2015-06-23 2024-07-17 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
SG11201811603WA (en) 2016-07-26 2019-02-27 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
CN106497949A (zh) * 2016-10-14 2017-03-15 上海交通大学医学院附属瑞金医院 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
KR102386890B1 (ko) 2017-05-22 2022-04-15 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
EA202090260A1 (ru) 2017-07-10 2020-05-08 ЮНИКЬЮРЕ АйПи Б.В. Средства и способы для генотерапии aav у человека
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
EP3790627A2 (en) 2018-05-09 2021-03-17 BioMarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
KR20210008491A (ko) 2018-05-14 2021-01-22 바이오마린 파머수티컬 인크. 청소년 대상체에서 aav 벡터의 안정한 발현
EP3810770A1 (en) * 2018-08-20 2021-04-28 Ucl Business Ltd Factor ix encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US20240293516A1 (en) * 2021-07-01 2024-09-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
DE59711957D1 (de) 1996-06-11 2004-10-28 Roche Diagnostics Gmbh Rekombinante blutgerinnungsproteasen
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
EP0971724B1 (en) 1997-02-14 2010-01-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
HUP0401534A3 (en) 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US20060292117A1 (en) * 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
NZ590187A (en) 2002-10-02 2012-07-27 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
ES2521682T3 (es) * 2003-05-21 2014-11-13 Genzyme Corporation Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
CN101006175A (zh) 2004-08-17 2007-07-25 Csl百灵有限公司 经修饰的维生素k依赖性多肽
DE502004008275D1 (de) 2004-08-19 2008-11-27 Gerd Baer Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
WO2006036502A2 (en) * 2004-09-22 2006-04-06 St. Jude Children's Research Hospital Improved expression of factor ix in gene therapy vectors
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
AU2005316476A1 (en) 2004-12-15 2006-06-22 University Of Florida Research Foundation, Inc. Chimeric vectors
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US20070172846A1 (en) * 2005-11-12 2007-07-26 Introgen Therapeutics, Inc. Methods for the Production and Purification of Adenoviral Vectors
ES2503365T5 (es) 2005-12-21 2017-10-31 Cnj Holdings, Inc Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
US7867484B2 (en) 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
WO2007101681A1 (en) * 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
US20080038224A1 (en) 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2007795B1 (en) * 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
BRPI0710671B8 (pt) * 2006-04-07 2021-05-25 Univ Texas uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
JP2009537609A (ja) 2006-05-24 2009-10-29 ノボ ノルディスク ヘルス ケア アーゲー 延長されたｆｉｘアナログ及び誘導体
US20070280906A1 (en) * 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
WO2008092643A2 (en) * 2007-02-01 2008-08-07 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
WO2008127654A2 (en) 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
JP5613876B2 (ja) 2007-10-15 2014-10-29 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 延長された半減期を備えるヒト第ｉｘ因子変異体
KR20110005862A (ko) * 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
CA2721362A1 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
EP2445513B1 (en) 2009-06-25 2014-08-27 The University of North Carolina At Chapel Hill Chimeric factor vii molecules
EA201290069A1 (ru) 2009-07-31 2012-07-30 Байер Хелскер Ллс Модифицированные полипептиды фактора ix и их применения
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
JP6879486B2 (ja) 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ Ｆｖｉｉｉおよびｆｉｘ用の最適化された肝臓特異的発現系
EP3313991B1 (en) 2015-06-23 2024-07-17 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения

Also Published As

Publication number Publication date
US20210238573A1 (en) 2021-08-05
HRP20181442T1 (hr) 2018-12-14
US20220090042A1 (en) 2022-03-24
US20220002702A1 (en) 2022-01-06
EP4219547A3 (en) 2023-10-18
CY1125885T1 (el) 2024-02-16
PL3581650T3 (pl) 2023-05-22
CA2737094C (en) 2018-02-20
US20200231958A1 (en) 2020-07-23
EP3581650A2 (en) 2019-12-18
US20160122740A1 (en) 2016-05-05
HRP20230259T1 (hr) 2023-04-28
US20170355973A1 (en) 2017-12-14
WO2010029178A1 (en) 2010-03-18
US9249405B2 (en) 2016-02-02
TR201813067T4 (tr) 2018-09-21
EP4032979B1 (en) 2024-05-01
US20110244550A1 (en) 2011-10-06
HUE061345T2 (hu) 2023-06-28
EP3581650A3 (en) 2020-03-25
EP4032979A1 (en) 2022-07-27
LTPA2023521I1 (da) 2023-08-25
US9982248B2 (en) 2018-05-29
FR23C1028I1 (fr) 2023-10-06
FIC20230026I1 (fi) 2023-07-25
HK1244507A1 (zh) 2018-08-10
CA2737094F (en) 2010-03-18
ES2687038T3 (es) 2018-10-23
HUS2300024I1 (hu) 2023-08-28
LT3581650T (lt) 2023-05-10
US10465180B2 (en) 2019-11-05
FI3581650T3 (fi) 2023-03-23
SI3581650T1 (sl) 2023-06-30
DK3581650T3 (da) 2023-03-13
US20210214704A1 (en) 2021-07-15
CA2737094A1 (en) 2010-03-18
EP4219547A2 (en) 2023-08-02
US20200199564A1 (en) 2020-06-25
ES2940323T3 (es) 2023-05-05
PT3581650T (pt) 2023-03-08
CY2023016I1 (el) 2024-02-16
US20200190498A1 (en) 2020-06-18
EP2337849B1 (en) 2018-06-13
PL2337849T3 (pl) 2018-11-30
EP2337849A1 (en) 2011-06-29
EP3252157A1 (en) 2017-12-06
US20180258413A1 (en) 2018-09-13
CY2023016I2 (el) 2024-02-16
EP3581650B1 (en) 2022-12-28
EP4032979C0 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
US10465180B2 (en) Factor IX polypeptide mutant, its uses and method for its production
JP7418519B2 (ja) 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
JP6571735B2 (ja) 止血を調節する組成物および方法
DK1891091T3 (da) Koaguleringsfaktor-X-polypeptider med modificerede aktiveringsegenskaber
EP2108045B1 (en) Improved fix-mutant proteins for hemophilia b treatment
EP1991255B1 (en) Coagulation factor x polypeptides with modified activation properties
JP2010527581A (ja) 組み換えヒト第ｉｘ因子及びその使用
BV Patent 2737094 Summary
WO2024193018A1 (zh) 一种凝血因子ix突变体及其应用
WO2014070349A1 (en) Factor ix variants
CN116590262A (zh) 一种凝血因子ix突变体及其应用
JP2012509670A (ja) 血液凝固促進剤としてのヘビ第五因子及び使用方法
KR20100039281A (ko) 변형된 인간 인자 Ⅶ／Ⅶａ 및 이를 함유하는 약학 조성물